Trial Information
Inclusion Criteria:
- Histologically proven classical Hodgkin lymphoma
- First diagnosis, no previous treatment, age: 18-60 years
- Stage IIB with large mediastinal mass and/or extranodal lesions, stage III or IV
disease
Exclusion Criteria:
- Composite lymphoma or nodular lymphocyte- predominant Hodgkin lymphoma (NLPHL)
- Previous malignancy
- Prior chemotherapy or radiation
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Response rate (RR) after six cycles of chemotherapy
Outcome Time Frame:
18 weeks
Safety Issue:
No
Principal Investigator
Peter Borchmann, Prof.
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Cologne, German Hodgkin Study Group
Authority:
Germany: Paul-Ehrlich-Institut
Study ID:
Targeted BEACOPP
NCT ID:
NCT01569204
Start Date:
October 2012
Completion Date:
December 2015
Related Keywords:
- Hodgkin Lymphoma
- Hodgkin Disease
- Lymphoma